Industry Overview - The Chinese medical artificial intelligence industry has significant growth potential, driven by policy support for rapid development [1] - The market size of China's medical AI is projected to grow from 2.7 billion RMB in 2019 to 8.8 billion RMB in 2023, with a compound annual growth rate (CAGR) of 33.8%. It is expected to reach 315.7 billion RMB by 2033, with a CAGR of 43.1% from 2023 to 2033 [1] Company Capabilities - The company has developed its own foundational large model, the "Xunfei Xinghuo Medical Large Model X1," which is the only medical deep reasoning model trained entirely on domestic computing power. In real-world testing, its general auxiliary diagnosis accuracy reached 94.0% [2] - As of July 2025, the X1 model's performance has been upgraded, achieving a general auxiliary diagnosis accuracy of 95.0%, with improvements in various metrics such as health consultation response rate at 91.5% [2] Product and Service Development - By the end of 2024, the company has provided products and services to over 70,000 grassroots medical institutions across more than 30 provinces and 670 districts, including over 40 of China's top 100 hospitals [3] - The company's revenue from grassroots medical services grew by 52.3% in the first half of 2025, while the revenue from regional management platform solutions surged by 178.1% [3] - The company's To C business, which includes imaging cloud platforms and post-diagnosis management, saw a revenue growth of 10% in the first half of 2025 [3] Financial Projections - Revenue forecasts for 2025 to 2027 are estimated at 850 million RMB, 1.01 billion RMB, and 1.21 billion RMB, corresponding to price-to-sales (PS) ratios of 10.7x, 9x, and 7.5x respectively [4]

Core Insights - The company reported a revenue of 299 million yuan for the first half of 2025, representing a year-on-year growth of 30.26% [1] - Gross profit reached 154 million yuan, with a year-on-year increase of 26.96% [1] - Despite ongoing losses, the net loss attributable to the parent company decreased to 74.09 million yuan, a reduction of 42.86% year-on-year [1] Business Segments - Government Segment: Revenue from grassroots solutions grew by 52.3% to 83.81 million yuan, with the core product "Smart Medical Assistant" covering 697 districts and counties and over 75,000 grassroots institutions, completing over 1.01 billion AI-assisted diagnostic suggestions [2] - Regional Solutions: Revenue surged by 178.1% to 57.63 million yuan, with AI infectious disease prevention solutions applied in multiple provinces [2] - Hospital Segment: Revenue from hospital solutions reached 52.86 million yuan, a decrease of 10% year-on-year, with the deployment of the company's large medical model in over 20 leading hospitals [2] - Consumer Segment: Patient management service revenue was 104 million yuan, up 10.1%, with the AI health assistant "Xunfei Xiaoyi" achieving over 24 million downloads and completing 140 million AI consultations [2]

Core Insights - Keda Xunfei reported a data resource of 61.74 million yuan in its 2024 annual report, making it the highest listed company in the software and information technology services sector in terms of reported amounts [2] - The company has been focusing on the intelligent voice and artificial intelligence sectors while also expanding into the smart healthcare sector, with R&D investment showing a consistent upward trend over the past three years [2][11] - In 2024, Keda Xunfei's R&D investment reached 1.996 billion yuan, a year-on-year increase of 24.62% from 1.602 billion yuan in 2023 [2] Smart Healthcare Development - Keda Xunfei's AI diagnostic assistant is expected to experience rapid growth, with significant room for penetration in the 2,843 counties across mainland China [7] - As of December 31, 2024, the AI diagnostic assistant has covered over 670 counties in more than 30 provinces, with applications in over 70,000 grassroots medical institutions, providing approximately 910 million AI-assisted diagnostic suggestions [7] - The accuracy of assisted diagnoses has improved from about 90% in 2021 to approximately 95% currently, while prescription review accuracy has also increased from about 93% to 95% [7] Competitive Landscape - Keda Xunfei has previously challenged the market share claims of its competitor, Yunzhisheng, which is attempting to go public after multiple unsuccessful attempts [8][10] - In 2023, Keda Xunfei's medical AI revenue was the largest in China's medical AI industry, with a market share of 61.5% in the CDSS market for grassroots medical institutions [11] - Other companies in the software services sector, such as Donghua Software and Shenzhou Digital, are also actively entering the smart healthcare field, with various AI-based products and solutions being developed [12][13] R&D Investment Comparison - Among the listed companies, Daily Interactive has the highest R&D investment as a percentage of revenue at 36.13%, followed by Keda Xunfei at 19.62%, while Shenzhou Digital has the lowest at only 0.32% [15]

Core Viewpoint - The article emphasizes that AI will not replace traditional Chinese medicine (TCM) but rather enhance the capabilities of TCM practitioners who can effectively utilize AI tools [6][21]. AI in Traditional Chinese Medicine - AI has the potential to assist in diagnosing and treating patients by providing reference prescriptions based on symptoms, as demonstrated by tools like DeepSeek [4][5]. - The consensus among industry professionals is that the future of TCM lies in practitioners who can leverage AI rather than AI replacing practitioners [6][21]. Current Applications of AI in TCM - Young TCM doctors reported limited use of AI during face-to-face consultations, primarily utilizing it for administrative tasks like creating teaching materials and work summaries [9]. - AI is seen as a tool for analyzing complex cases and expanding diagnostic thought processes, particularly in Western medicine contexts [10]. Challenges in AI Implementation - The complexity of TCM's theoretical framework poses challenges for AI, as it requires structured data for effective training, which is often lacking [11]. - AI struggles with the "four diagnostic methods" (observation, listening, inquiry, and pulse-taking) essential in TCM, leading to potential misdiagnoses [12]. Future Directions for AI in TCM - AI can improve patient-doctor matching by assessing TCM practitioners' capabilities and guiding patients to suitable doctors based on their symptoms [17]. - In the diagnostic and treatment phases, AI can assist in analyzing patient information and drafting medical documents, allowing doctors to focus more on patient interaction [18]. AI's Role in Enhancing TCM Practice - The development of AI tools aims to elevate the diagnostic capabilities of TCM, with products like AI-assisted consultation and digital representations of renowned TCM practitioners being explored [19]. - AI can also facilitate patient follow-ups and health management, enhancing the overall patient experience [20]. Conclusion - The article concludes that the integration of AI into TCM is not about replacement but about collaboration, where AI acts as a supportive tool for practitioners to improve their practice and patient outcomes [21].